‘So far this year, we’ve launched Eliquis in several markets all over the world, have begun dealing with AstraZeneca to bring Byetta and Bydureon to individuals outside the U.S., and also have been finding your way through the presentation of essential medical data across our pipeline.’ About Bristol-Myers Squibb Bristol-Myers Squibb is a worldwide biopharmaceutical company whose objective is to find, develop and deliver innovative medicines that help individuals prevail over serious diseases.. Bristol-Myers Squibb reports initial quarter 2013 financial results Bristol-Myers Squibb Organization reported financial results for the first quarter of 2013, and confirmed GAAP EPS and non-GAAP EPS assistance ranges for 2013.But progress in these research was painstakingly slow. Related StoriesLatinos with African ancestry at higher risk for glaucomaMatricellular proteins may be crucial therapeutic targets for common ocular disordersCharles Bonnet syndrome: an interview with Dr. Dominic ffytche The pace accelerated significantly with the completion of the NIH-led Individual Genome Project in 2003, and the introduction of technology to quickly and cheaply decode each person's unique genome. Quickly, Dr. Wiggs and her Harvard colleagues merged their attempts, and began working with researchers at other sites. In 2012, with funding and additional guidance from NEI, Dr. Wiggs began leading the NEI Glaucoma Human being Genetics Collaboration . This consortium includes 12 organizations across the U.S., and has collected genetic samples from approximately 4,500 sufferers and about 20,000 people without the condition.